The short version of incretin receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
vary as decreasing monotonic functions of temperature, and the enrichment of multiply D-substituted > multiply 13C-D-substituted > multiply 13C-substituted isotopologues for a same number of substitutions (as shown in this figure).
==== Weak partial androgenic activity ==== CPA, like spironolactone and other steroidal antiandrogens such as chlormadinone acetate and megestrol acetate, is actually not a pure antagonist of the AR – that is, a silent antagonist – but rather appears to be a very weak partial agonist. Clinically, CPA generally functions purely as an antiandrogen, as it displaces much more efficacious endogenous androgens such as testosterone and DHT from interacting with the receptor and thus its net effect is virtually always to lower physiological androgenic activity. But unlike silent antagonists of the AR like nonsteroidal antiandrogens such as flutamide, bicalutamide, and enzalutamide, CPA, by virtue of its slight intrinsic activity at the AR, may be unable to fully inhibit androgenic signaling in the body, which may persist to an extent in some tissues such as the prostate gland. In accordance with its albeit weak capacity for activation of the AR, CPA has been found to stimulate androgen-sensitive carcinoma growth in the absence of other androgens, an effect which could be blocked by co-treatment with flutamide. In one study in rodents, DHT-stimulated prostate weight remained 40% above controls with administration of CPA even at the highest dosage, while flutamide was able to completely block the stimulatory effects of DHT. In addition, CPA alone increased prostate weight by 60%, whereas flutamide had no effect.
=== Menu options === The menus below are adapted from lists available on the website of the Defense Logistics Agency (DLA). UGR menus are regularly modified to improve their variety, nutrition, and efficiency. As the DLA does not regularly publish UGR menus. The lists below use the 2020 menu for the UGR-H&S, 2023 menu for the UGR-A, 2014 menu for the UGR-M, and 2021 menu for the UGR-E. Note that the lists below do not include milk, bread, fruit, or salad supplements, or items standard to most UGRs such as regular coffee and hot sauce.
==== Droplet-based PCR ==== Polymerase chain reaction (PCR) has been a vital tool in genomics and biological endeavors since its inception as it has greatly sped up production and analysis of DNA samples for a wide range of applications. The technological advancement of microdroplet scale PCR has enabled the construction of single-molecule PCR-on-a-chip device. Early single molecule DNA replication, including what occurs in microdroplet or emulsion PCR, was more difficult than larger scale PCR so much higher concentrations of components were usually used. However, fully optimized conditions have minimized this overload by insuring single molecules have an appropriate concentration of replication components distributed throughout the reaction cell. Non-droplet based microfluidic PCR also faces challenges with reagent absorption into the device channels, but droplet-based systems lessen this problem with decreased channel contact. Using water-in-oil systems, droplet PCR operates by assembling ingredients, forming droplets, combining droplets, thermocycling, and then processing results much like normal PCR. This technique is capable of running in excess of 2 million PCR reactions in addition to a 100,000-fold increase in the detection of wild-type alleles over mutant alleles. Droplet-based PCR greatly increases the multiplexing capabilities of normal PCR – allowing for fast production of mutation libraries.
Sources: en.wikipedia.org
=== Protein digestibility === For many foods, the quantity of amino acids absorbed by the body may differ significantly from the quantities of amino acids originally present in the food, as a result of various digestive processes. The digestion of proteins begins in the stomach and is largely complete by the time food exits the small intestine. However, digestion may be reduced by antinutritional factors or the presence of other food components such as dietary fiber. Gut microbes may also impact protein digestion due to their own digestion of protein. Digestibility may also differ between amino acids. While the fecal digestibility of the whole protein is likely a fair approximation of the digestibility of individual amino acids for non-legume (beans, peas, lentils) proteins with a maximum difference of 10%, with legume proteins, the digestibility of methionine, cystine, and tryptophan can be overestimated.
the area of contact was larger than that predicted by Hertz theory, the area of contact had a non-zero value even when the load was removed, and there was even strong adhesion if the contacting surfaces were clean and dry. This indicated that adhesive forces were at work. The Johnson-Kendall-Roberts (JKR) model and the Derjaguin-Muller-Toporov (DMT) models were the first to incorporate adhesion into Hertzian contact.
== Thymosin as a hair loss treatment == The process of hair growth utilizes many cellular and molecular mechanisms common to angiogenesis and wound healing. While studying the influence of thymosin beta-4 (Tβ4) on wound healing, Philp et al. accidentally found that hair grew more rapidly around the edges of wounds. In due course, they showed that Tβ4 induced rapid hair growth on the dorsal skin of healthy mice.
various Amanita mushrooms: muscimol Amanita muscaria: ibotenic acid and muscimol Claviceps purpurea and other Clavicipitaceae: ergotamine (not psychoactive itself but used in synthesis of LSD) psilocybin mushrooms: psilocybin and psilocin Psychoactive animals:
=== Forensics === A ninhydrin solution is commonly used by forensic investigators in the analysis of latent fingerprints on porous surfaces such as paper. The amino acids present in the minute sweat secretions that gather on the finger's unique ridges transfer to surfaces that are touched. Exposure of the surface to ninhydrin converts the amino acids into visibly colored products and thus reveals the print. The test solutions suffer from poor long-term stability, especially if not kept cold. To further enhance the ability of ninhydrin, a solution of 1,2-indandione and zinc chloride (IND-Zn) can be used prior to ninhydrin. This sequence leads to greater overall reaction of the amino acids, possibly by IND-Zn helping to release them from the surface for the subsequent ninhydrin reaction.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.